Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation

Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation

“…Although these publications may suffer from publication bias of positive outcomes, overall they show promising results. [8][9][10][11][12][13][14][15] In this preliminary study in which we recruited 20 alloSCT recipients with posttransplant severe thrombocytopenia, we have tried to perform a careful and thoughtful descriptive analysis to emphasize the importance to keep working on improving the treatment in common and relevant post-SCT complications.…”

“…7 However, the reported experience on their use after alloSCT is currently limited. [8][9][10][11][12][13][14][15] In this study, we retrospectively evaluated TPOa efficacy and safety in 20 consecutive adult alloSCT recipients who received either romiplostim or eltrombopag as a compassionate use for treating severe thrombocytopenia postengraftment in alloSCT recipients, exploring the potential predictive factors of response in this cohort.…”

Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation

“…Bruno et al reported that SFPR not due to recurrent malignancy was observed in 20% of patients undergoing allogeneic HCT and was associated with serious complications and poor outcomes [21]. Seven reports have described a total of 22 patients with SFPR who were treated with a TPO-R agonist after HCT (Table 4) [13][14][15][16][17][18][19]. All of these patients were treated with romiplostim and 20 (91%) achieved transfusion independence.…”

“…Their safety and efficacy have been reported for idiopathic thrombocytopenia purpura [8] and for thrombocytopenia in other conditions [9][10][11][12]. Several studies have reported the efficacy of romiplostim for the treatment of thrombocytopenia after allogeneic HCT [13][14][15][16][17][18][19], but data on eltrombopag treatment after allogeneic HCT are lacking. We report our experiences with 12 consecutive patients treated with eltrombopag for severe thrombocytopenia after allogeneic HCT at our center.…”

Use of thrombopoietin receptor agonists after hematopoietic progenitor cell transplantation

“…Twelve reports of 68 patients treated with romiplostim for prolonged thrombocytopenia following HCT were included in this review as shown in Table 2. [38][39][40][46][47][48][49][50][51][52][53][54] An additional 70 patients treated with romiplostim were reported in three articles that also included patients treated with eltrombopag as shown in Table 4. [55][56][57] Of the romiplostim treated patients, four reports included pediatric patients.…”